Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
Scleroderma, Systemic | Digital UlcerThis study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Diagnosis of systemic sclerosis (scleroderma)
* At least one "active" digital ulcer
* Medication for systemic sclerosis unchanged for 30 days
Exclusion Criteria:
* Infection or gangrene in ulcer
* Citrus allergy
* Unstable heart, kidney, or liver disease
* Active infection of any type
* Current cancer treatment or uncured cancer
* Pregnancy or breast feeding
Study Location
Saint Joseph Health Care Centre
Saint Joseph Health Care CentreLondon, Ontario
Canada
Contact Study Team
Mount Sinai Health System
Mount Sinai Health SystemToronto, Ontario
Canada
Contact Study Team
Dalhousie University
Dalhousie UniversityHalifax, Nova Scotia
Canada
Contact Study Team
Sutton, MD
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contact Study Team
Larche', MD
The Ottawa Hospital
The Ottawa HospitalOttawa, Ontario
Canada
Contact Study Team
Maltez, MD
- Study Sponsored By
- Primus Pharmaceuticals
- Participants Required
- More Information
- Study ID:
NCT06256575